IEEE Foundation



Protyon provides an analysis service that examines the effect of mutations in specific proteins targeted for treatment in lung cancer. Protyon uses molecular structures to choose the best therapy. Currently focusing on mutations in EGFR and other lung cancer drivers. Working closely with the Molecular Tumor Board at the UMCG #umcg and patient organizations across Europe.

Protyon became an IEEE Entrepreneurship Stars Recipient at Hello Tomorrow 2024.